Thus, inhibition of AKT should be beneficial for patients with overgrowth syndromes driven by activating mutations of PIK3CA and AKT. Generation of mouse models to reflect the phenotypes of patients with overgrowth syndromes is challenging. This evidence concerns the gene AKT1 and overgrowth syndrome.